Powder: -20°C for 3 years | In solvent: -80°C for 1 year
NUCC-390 是新型的选择性小分子 CXCR4 receptor 受体激动剂。NUCC-390 可以诱导 CXCR4 受体的内化,作用方式与 AMD3100相反。NUCC-390 在动物模型中,有助于神经退行性变后神经功能恢复。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 1,480 | 现货 | ||
5 mg | ¥ 3,110 | 现货 | ||
10 mg | ¥ 4,570 | 现货 | ||
25 mg | ¥ 7,260 | 现货 | ||
50 mg | ¥ 9,790 | 现货 | ||
100 mg | ¥ 13,200 | 现货 | ||
500 mg | ¥ 26,300 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 3,550 | 现货 |
产品描述 | NUCC-390 is a novel and selective small-molecule CXCR4 receptor agonist. NUCC-390 induces internalization of CXCR4 receptors and acts in an opposite way of AMD3100. NUCC-390 promotes nerve recovery of function after neurodegeneration in vivo. |
体外活性 | NUCC-390 (10 μM) produces strong (Ca)i response, but this effect can be blocked by the known potent and selective CXCR4 antagonist AMD3100. NUCC-390 (10 μM; pre-treatment 30 mins) leads to increased levels of pERK, it has the capability of stimulating signaling activity downstream of CXCR4 receptors. NUCC-390 (10 μM; 2 hours) can induce CXCR4 receptor internalization, and non-treated cells exhibit some diffuse expression of CXCR4-YFP throughout the cytosol and clear expression in the cell membrane in HEK cells[1]. NUCC-390 (0-1.25 μM; 24 hours) boosts axonal growth in cultured cerebellar granule neurons (CGNs) via CXCR4[2]. |
体内活性 | NUCC-390 (hind limb injection; 3.2 mg/kg; twice daily; 3 days) contributes to the functional and anatomical recovery of the neuromuscular junction (NMJ) following an acute nerve terminal damage by α-LTx in CD-1 mice[2]. |
分子量 | 395.54 |
分子式 | C23H33N5O |
CAS No. | 1060524-97-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 60 mg/mL (151.69 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.5282 mL | 12.6409 mL | 25.2819 mL | 63.2047 mL |
5 mM | 0.5056 mL | 2.5282 mL | 5.0564 mL | 12.6409 mL | |
10 mM | 0.2528 mL | 1.2641 mL | 2.5282 mL | 6.3205 mL | |
20 mM | 0.1264 mL | 0.632 mL | 1.2641 mL | 3.1602 mL | |
50 mM | 0.0506 mL | 0.2528 mL | 0.5056 mL | 1.2641 mL | |
100 mM | 0.0253 mL | 0.1264 mL | 0.2528 mL | 0.632 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
NUCC-390 1060524-97-1 Autophagy GPCR/G Protein Immunology/Inflammation CXCR NUCC 390 NUCC390 Inhibitor inhibitor inhibit